.Merck defeats earnings desires, raises sales outlook on solid need for leading medicines like Keytruda CNBCMerck & Co. (MRK United States) Defeats Income Projections as Keytruda Purchases Rise BloombergMerck Stock: Pharma Titan Posts Sturdy End Results, Yet Overview Drops Short Client's Organization DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck trumps profit and purchases desires in the middle of Keytruda strength, yet delivers combined full-year expectation MarketWatch.